Extremely contagious superbacteria … the term freezing in the veins of patients and doctors, because how to fight the diseases caused by them, since they show almost complete resistance to most antibiotics known to us.
Bacteria are very sly organisms, not only that some of them can boast of primary resistance to antibiotics, they evolve very quickly, adapting to new conditions and reacting to them with secondary resistance. One of the most terrifying of these superbacteria is Klebsiella pneumoniae, which is a pneumonia rod, which once only spread terror in hospitals, and now – in a much more deadly and more difficult to treat form – is spreading all over the world and it’s difficult to stop it torrent websites directory.
The pneumonia rod is the real bane of hospitals, often attacking patients who are there for other reasons. It can cause some types of pneumonia, infections of the circulatory system, infections in the gastrointestinal tract, bones, joints or urinary tract, the infection of the latter sometimes leading to sepsis – in newborns it is also an etiological factor of meningitis. In addition, it has developed resistance to many antibiotics, including those called last chance.
According to David Rosen, co-author of the new research: – Pneumonia was for years only a hospital problem, so even if treatment was difficult, its impact on society was small. Now we are observing strains that are malignant enough to cause death or serious illness even in healthy people. Over the past five years, antibiotic-resistant and extremely contagious bacteria have been combined to form completely new super-contagious strains. This is very scary.
Fortunately, a new vaccine can help control the situation, which shows promising results when tested on mice – this may be a better option because in the case of difficult-to-kill bacteria it is easier to prevent than cure. Scientists from Washington University in St. So they set themselves the goal of creating the right vaccine, aimed at two specific strains, K1 and K2, which together are responsible for 70% of cases caused by this bacterium. In the first tests, the vaccine was administered three times (at bi-weekly intervals) to a group of 20 mice, which were then treated with K1 and K2.
Only 20% of K1 infected and 70% of K2 infected mice survived in the placebo group, while in the vaccinated group the survival was 80 and 100%, respectively. In short, the vaccine works very effectively, so soon its clinical tests will start, thanks to which it will be possible to check its operation and give it to people as soon as possible before a real pandemic occurs.